05:40 AM EDT, 05/08/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target price to USD33 from USD37, implying a 2026 P/E of 14.8x. This is broadly in line with its three-year historical forward P/E of 15x. While we see positives from its stronger positioning following the completion of the 12-Point Plan and additional upside from the RISE strategy, our optimism is tempered by rising execution risk in the U.S. Knee Implant business. Our EPS estimates remain unchanged. Smith & Nephew's ( SNN ) Q1 2026 underlying revenue growth of 3.1% decelerated sequentially across all segments, particularly Orthopaedics due to U.S. Knee Implants weakness. SN reiterated its 2026 guidance of 6% underlying revenue growth and USD1.3B trading profit. We expect upcoming launches and continued execution of the RISE strategy to support growth momentum, but execution on U.S. Knee Implants remains critical to monitor. The cementless LANDMARK launch is an important catalyst to address persistent challenges in the knee business, in our view.